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T he inte ractio n of prostag landin O2 (PGD 2) and hi stamin e 
in hum an skin was studied by intrader lll al injection o f the 
cOIllPo unds alo ne o r in co mbin ation in health y vo lunteers. 
Respo nses were reco rded by m easurement of areas of w hea l 
a nd eryth em a, and changes in cutaneous blood Row quan-
tified using a laser D o ppler Row m eter. The effect of a 
near-thresho ld dose of PGD 2 on hista min e dose-respon se 
relatio nships and o n the response to a sin gle low dose of 
histam ine were exa min ed . Histamin e ca used dose-related 
inc reascs in blood Row and in areas of wheal and erythema 
in hUlll an skin . Pros tag landin O2 caused dose-related in-
creases in bl ood Rowand erythcm a area, but no t wheal 
I ntradc rm al injectio n o f prostagla ndin O2 (PGD2) ca uses er-ythema and w hea lin g in hum an skin . alth oug h it is approx-imately 5 tim es less po tent than prostaglandin E2 [1 ,2J. PGD2 is the m aj o r cyclooxygenase produ ct of the hum an m as t cell and is released in parallel w ith hi stamine by pass ively sen-
s itized human skin in vitro 131 and by hum an pulmonary mast 
cd ls in cubated w ith anti-l gE 14,5 1. Prosta glandin D2 generati on 
has also been dem o nstrated in vivo in immedi ate all erg ic reactio ns 
in hum an skill [6 1. Recell[ w ork has demonstrated co ncurrent 
release o f immuno reactive PG I 2 and hi stamin e ill[o the venous 
b lood drainin g co ld-challenged arms in patients w ith co ld urti-
ca ria , alth ough the peak hi sta mine concentrati on was between 
271- and l242-fo ld g reater th all the peak concentration o f PGD2 
o n a molar bas is 17 1. Studies on patients w ith hea t urti ca ri a have 
y ielded similar results [81. PG D2 released in the am o unts measured 
is unlik ely to co ntribu te directl y to the cutaneous chan ges in 
urtica ria, but it ma y ac t synergisti call y w ith his tamine. Indeed , 
PG D2 has been shown to potentiate the in crease in vascul ar 
pe rm ea bility indu ced by his ta min e in rat skin 111 . 
We have therefore in ves ti ga ted th e inte ract ions between PGD2 
and histamine in hum an skin by meas urin g w heal and erythema 
a reas and cutaneous blood Row, fo ll owin g intraderm al injectio n. 
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area, in the dose range used. When thc co mpo unds we re 
inj ected toge ther, PGD 2 did not po tenti ate the in crease in 
blood Rowand areas of wheal and erythema du e to hi s-
tamine. The m odes t aug m entati on of hi stamine respo nse 
in the presen ce of PGD2 could be attributed to sUlllm ati on 
alo ne. The role ofPGD 2 in cutaneous di so rders such as the 
ph ys ica l urti ca ri as , in which its relcase has becn dem o n-
strated , is therefo re lln certain . In the am ounts mcasured in 
the urti cari as, it is unlikely alone to ca use a sig nifi ca nt 
cutaneO ll S response; no r does it appea r to act by potenti a-
tion of the respon se to histamine. J III vest D erll1r1tv/ 89: 
245- 248, 1987 
MATERIALS AND M ETH ODS 
Subjects Nine hea lth y volunteers (6 men , 3 wo m en, age range 
25-73), none of w ho m was takin g any m edicati on, gave in for l11 ed 
consellt to participate in the stud y, w hich was appro ved by th e 
Resea rch Subcommittee o f St. Jo hn 's H os pital. 
Intradennal Injections Stock solutions ofPGD2 (60 J.L M, Sigma 
C hem ica l Co., St. Lo uis, Missouri) and hi stamin e dih ydrochl o r-
ide (180 J.LM , Sig ma) were prepared in phosphate-bu ffered saline 
(fin al pH 7.2) and stored at -70°C, On the day of the ex periment , 
appro pri ate dilutions were made in phosp hate-buffe red sa line and 
sterilized by filtratio n (millipo re, Mill ex- GS 0.22 J.L M) immedi-
ate ly prio r to usc . Fifty mi cro liter volumes of histam in e, PGD 2, 
or a mixture of th e 2 compounds were inj ected intraderm all y into 
the back usin g a 25-gauge needle, aliocHin g the inj ectio ns ran-
do ml y to d iffe rellt sites in o rd er to redu ce an y bias fro m spatia l 
va riabi lity in cutan eous respo nse I'J I. All ex perimCllts were ca rr ied 
out at th c same tim e of day, at an ambient temperature of 23°C. 
Measurement of Areas of Wheal and Erythema A n:as o f 
w hea l and eryth em a were m eas ured at va rious time illterva ls afte r 
injec tion by t rac in g th e o utlin es onto a transparCllt po lythl'ne 
sheet. T he sheet was photocop ied and th e w hea l and Rare il11 ages 
cut out and weighed. From this, the areas co uld be calculated. 
Measurement of Cutaneous Blood Flow A laser Doppler 
Row mete r (Perim ed II , PeriRu x, Sweden) was uscd for thc quan-
titati ve measurl' Jll CIlt of changes in mi crocirculato ry Row indu ced 
b y histJ mine and PGD2. This nonin vasive o pti ca l tech niquc has 
been fo und to be a va lu able Jnd accurate l11 eth od in the stud y o f 
cutaneous inRallllll ation 110- 121. Preliminary ex pcrim ents showed 
that read in gs were va ri able w hen the pro be was pl aced OVl'l' th e 
wheal ; however, meas urel11cn ts taken w ithin th c Rare but adj acent 
to th c w hea l gave reprodu cibl e resu lts th at co rrelated well 'vv ith 
a visua l assess m ent o f th e deg ree o f ery th ema . All measurem ents 
were th erefo re m ade wi th th e probe immediately adj acent to th e 
w hea l, as reco mJll ended by Serup and Stabl'l'g 11 2]. The probe 
0022-202xm7/S03.S0 Co pyri ght © 1987 by Th e Society fo r 1n vcs tig:lt ivc Dermato logy, [n e. 
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Figure 1. Dose-response curves for area of erythema and cutaneous blood 
flow changes induced by intradermal injection of prostaglandin D2 in 
healthy volunteers. Erythema area (f riallg{es) was measured 10 min afte r 
injection. Cutancous blood flow (squares) was mcasured 30 min afte r 
injection. Each point represents the mean ± SEM; n = 3. 
was held in position for 2.5 min at each site, w ith the usc of a 
perspex ho lder taped to the skin . This period of application produced 
a stable blood fl ow reading at each site and the mean va lue (V) 
over the 2.5 min period was then recorded . Readings were also 
taken from normal skin at 6 different sites on the back and the 
mean o( these values subtracted from the readin g obtained at 
inj ected sites, to g ive the in crement in cutaneous blood fl ow in-
duced by the inj ection . 
PGD2 Dose-Response Curves Dose- response relationships for 
PGD2 alone were estab lished by injectin g doses of 3, 9, 28, 85, 
284, and 851 pmol in each of 3 subj ects and measuring th e re-
sponses at 10 min (areas of w heal and erythema) and 30 min 
(cutaneous blood flow). In the rema inin g 6 su bj ects, the erythema 
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threshold of PGD2 was determined w itho ut establishin g a com-
plete dose-response relationship. For the purposes of this stud y, 
the dose of PGD? referred to as the threshold was that w hi ch 
elicited an e ryth el~a that was confin ed to the area of the w heal. 
Histamine Dose-Response Curves in the Presence and Ab-
sence of a Near- Threshold Dose of PGD2 Dose-response 
relationships fo r hi stamine alone we re establi shed by injecting 
doses of 27, 90, 270, and 900 pm ol, and 2.7 and 9 nl11 0 l in each 
of 7 subjects. Areas of erythem a we re measured in all 7 subj ects; 
cutaneo us blood fl ow and w hea l areas we re measured in five. 
Laser Doppler measurements were ca rri ed out at 5 min; areas of 
w hea l and erythema were measured at 10 min . In each volunteer, 
the same doses of hista min e were then inj ected in the presence of 
a dose of PGD 2 at o r a Littl e above the thresho ld dose, and the 
m easu rements repeated. 
Effects of a Near-Threshold Dose ofPGD2 on the Response 
to a Single Dose of Histamine (90 pmol/site) The effects of 
a dose of PGD2 at o r a little above the threshold dose on the 
response to a si ngle low dose of hj sta min e (90 pmol/site) were 
exam ined in 6 subj ects . For thi s experim ent, each inj ect ion of 
histamine alone and histamine with PGD2 was done in triplicate. 
Areas of w hea l and erythem a were m easured at 3, 6, and 15 min ; 
cutaneous blood fl ow was measured at 5 (7 subj ects), 8, and 13 
m1l1. 
RESULTS 
PGD2 Dose-Response Curves Intraderm al inj ections ofP GD2 
alone, in amounts ranging from 3- 851 pmol per site, caused dose-
related erythema. T he eryth ema was darker than that induced by 
histamin c and was of longe r durat ion , attainin g a m ax imum at 
15-30 min and disappearing by 5 h. An erythem a threshold dose 
for PGD2 in each subj ect was established and found to va ry frolll 
3-85 pmol. The dose-response curve obtained for PGD2-induced 
erythe m a is shown in Fig 1. In the amounts used, PGD2 only 
elicited a minor degrec of w healin g, the area of w hich was not 
dose-related. H owever, a dose-response relationship was found 
for cu taneous blood fl ow (Fig '1). 
T here was a large intersubj ect variation in the responses to both 
PGD2 and hista mine, accollnting for the large sta ndard errors 
obtai ned . 
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Figure 2. Dose-respollse curve for erythema area, wheal area, and cutaneOllS blood flow changes induced by intraderma l injection of histam ine a lon~ 
and with a ncar-threshold dose of prostaglandin D2, in hea lth y volunteers. Sql/are = histamine alone; circle = prostaglandin D2 alone; trill llg{c '" 
histamine + prostaglandin D2. Each point represents the mean ± SE M. a, Area of erythema, measured 10 min after inject ion; n = 7. Ii , Area of 
whea l, measllred 10 min after injection; n = 5. c, Cutaneous blood flow change, measured 5 min afte r injection ; n = 5. 
VOL. 89. NO.3 SEI'TEMBE R 1987 
Histamine Dose-Response Curves in the Presence and Ab-
sence of a Near-Threshold Dose of PGD2 Intradermal in-
jecti ons o f hista min e, in quantities ran gin g from 27 pmol to 9 
nmol, caused dose-related erythema, w hea lin g, and increases in 
cutaneous blood Row. The ery thema was ma ximal at 5 min and 
had disappeared by 1 h. Whea lin g disappeared wi thin 3 h. The 
dose-res ponse curves for cutaneous blood Row were variab le from 
subj ect to subj ect; in so me cases there was a nea r-1in ea r relation-
ship between blood Ro wand hi stamin e dose over the dose range 
examined , whereas in o thers the lowest dose of hista min e used 
el icited near-ma xim al blood Row w ith li ttle further in crease at 
hi gher doses . 
T he effects of a nea r-thres ho ld dose of PGD2 on histamine-
induced erythema was in vestiga ted in 7 separate experiments and 
o n hista min e-induced w hea lin g and curaneous blood Row in 5 
experiments. Pros tag landin D 2 consistentl y ca used a slig ht left-
ward displacement of the dose-response curves (Fig 2). This dis-
placem en t appea red to be no g rea ter than th at w hi ch wou ld be 
expected from summation of th e indiv idual responses to hista-
mine and PGD2. 
Effect of a Near-Threshold Dose of PGD2 on the Response 
to a Single Dose of Histamine (90 pmollsite) The results of 
these experiments arc summari zed in Tables I and II and have 
been ex pressed as mean ± SEM of val ues in all subjects at each 
time interval. At this concentration, histamine ca used erythema, 
w healing, and increased blood Row. As can be seen from the 
Tables, the addition of PGD2 produced on ly a modest in crease 
in response. N one of the differences was statistica lly signifi ca nt 
except for erythem a area measured at 15 min after inj ection (p < 
0.05, Wilcoxo n's test) . T he prin cipal difference observed was that 
th e responses to th e histamine and PGD2 co mbinatio n were m o re 
purple in color and longer lasting than the responses to histamine 
alone. This effect explains th e somewhat larger difference in er-
ythem a area between histamine with and without PGD2 observed 
a t 15 min, compared with the 3 and 6 min readings. 
D ISCUSSION 
T h e results of this study suggest that , under the cond itions used, 
PGD 2 does not po tentiate th e res ponse of hum an skin to hista-
mi ne, w ith respect to the size of the eryth ema and wheal, a,~d 
cu taneous blood Aow. The m odes t aug m entation of responses 111 
the presence of PG02 ca n be attributed to summation alone. These 
results confirm and extend those of a recent stud y by Barnes and 
Heavey [131. w ho exa mined the effect of PGD2 on whea l response 
to intraderma l his tamine, and fou nd no effect on whea l area or 
volume. Since Flower and associates [1] demonstrated potentia-
tion of histamine-induced vascular permeability increases by PGD2 
in ra t skin, it is likel y that species differences exist in the cutaneous 
responses to these compounds. 
The amounts of PGD2 req uired to ca use erythema and edema 
in this stud y arc g rea ter than those meas ured in blood durin g heat 
Table I. E ffect of a N car-Threshold Dose of Prostaglandin 
D 2 (PGD2) on the Areas of E rythem a and Wh eal In du ced b y 
the In tradermal Inj ection of 90 pm o l Hi stamin e (H) in 
Health y Volunteers 
Time Number of Reagents Wheal Area Erythema A rca 
(mi n) Subjects Injected (1111112) (111 111 2) 
3 6 H 77 ± 9 735 ± 167 
H + PGD2 77 ± 8 861 ± 143 
6 6 H 78 ± 9 G4 1 ± 184 
H + PCD2 84 ± 10 756 ± 129 
15 6 H 82 ± 10 467 ± 159 
H + PCD2 86 ± 8 625 ± 182 
Read in gs arc mad e ;'I t 3- 15 min intervals after injectio n. V:t1ucs represent I11 C:lII 
± SEM. 
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Table II. Effect of a N ea r-Threshold Dose of Prostaglandin 
O2 (PGD2) on the C utaneous B lood Flow C hanges In du ced by 
the Intradermal Injection of 90 pmol Histamine (H) in 
H ealthy Volunteers 
C utaneous m ood 
Til11c Number of Heagents Flow C han ge 
(min) Subjects Injected (V) 
5 7 H 1. 22 ± 0.1 5 
H + PGD, 1.32 ± 0.1 5 
8 6 H 1.32 ± 0. 17 
H + PGD1 1.32 ± 0. 15 
13 3 H 1. 34 ± 0.1 3 
H + PGD2 1. 37 ± 0.08 
Headi ngs JrL" mad l' at 5- 13 mill illterva ls arter injecti oll . Va lu es represent I1H.'an 
± SEM. 
and cold urtica ri ,1. T hus PG02 is unlikely to contribute directl y 
to the cutaneo us chan ges observed in these conditi ons. Further-
more, since w e have dem onstrated that PG02 docs not po tenti ate 
the vascul ar responses to histamin e, which is released concur-
rentl y, it is unlikel y that a synerg istic interac tion between th e 2 
compounds occurs with res pect to increased permea bility and 
erythema. The lack of a ro le of PGD2 in hea t and cold urti caria 
would also be supported by the therapeutic ineffectiveness o f 
cyclooxygenase inhibito rs, such as indomethacin , in th ese con-
ditions (A. Ko bza Black, personal communication). 
Prostaglandin D2 prod ucti on by mast cells is believed to con-
tr ibute substantiall y to sympto ms such as Aushing and hypo ten-
sion in sys temi c mastocytos is [1 4]. but its biologic ro le in skin 
diso rders remains unclear. The poss ibi lity that th e PGD2 metab- . 
o lite, 9a, 1-1 J3-pros taglandin F2 [1 5] has a role in the mediation 
of cutaneolls inAammation is currentl y under in ves tiga tio n. 
We tllallk Dr. Pal/liM Dowd (Middlesex Hospital, Lcmdoll , U. K.) for til e lISe 
of til e laser Doppler .flolll /II etcr , 
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